News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Health Robotics Reports 28 New Agreements in 1Q2013, Including 18 Contracts in the United States of America



4/22/2013 10:59:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOZEN, Sud-Tirol, Italy, April 22, 2013 /PRNewswire/ --

Health Robotics reported 28 new contracts in 1Q2013, including 12 new Robots [versus 6 Robots in 1Q2012; 8 for Oncology and 4 for non-hazardous IVs] and 16 new i.v.SOFT workflow software agreements [versus 11 i.v.SOFT contracts in 1Q2012]. After a dominant record overseas with almost 300 global installations outside the USA since 2007, http://www.health-robotics.com/en/installations/, Health Robotics is now also the clear leader in the United States' Sterile Compounding Automation sector, with 30 Robots and 50 i.v.SOFT workflow installations, only two years after directly entering the North American market.

Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "I'm very pleased with such a strong sales-kickoff for Health Robotics in the United States this year. As predicted, Health-System pharmacists in the USA now recognize the undeniable fact that Health Robotics' second generation modular architecture of integrated and networked medical devices are fully automated, offer 3 to 4 times faster speed/throughput, for less than half the price, size, and weight than its global competitors([1]) , delivering payback periods/R.O.I. of less than 1 year, http://www.nbcnews.com/video/nbcnews.com/51575854/#51575854."

During the last quarter, Health Robotics and/or its sales channel network signed 28 new installations for either Batch and/or Patient-Specific Sterile Compounding Automation at: Monroe Carrell Children's Hospital at Vanderbilt University [TN], Huntsville Hospital Health System [AL], William W. Backus Hospital [CT], Kameda Hospital [Japan], Recep Tayyip Erdogan University Hospital [Rize, Turkey], Memorial Okmeydani Hospital [Istanbul], and Sisli Etfal University Hospital [Istanbul], amongst others, plus the exclusive 5-year contract with Amerinet.

About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 350 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solution. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies([) (2) (]) (,) ([) (3) (]) ] to greatly contribute to ease hospitals' growing pressures to improve patient safety([2]) , increase throughput, and contain costs([) (2) (]) . Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug([) (2) (]) and diluent([) (2) (]) exchange errors, improve drug potency([3]) , decrease other medical mistakes and sterility risks, work more efficiently([) (2) (]) , reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com

--------------------------------------------------

1. Competitors: Intelligent Hospital Systems/RIVA, Fresenius Kabi/MDS, Baxter/Baxa, and Loccioni.

2. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

3. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin(R), Remicade(R), and Herceptin(R). Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

For additional information, please contact:

perez@health-robotics.com

Phone +1-786-417-1251

SOURCE Health Robotics

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES